Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
AssigneeWaratah Pharmaceuticals, Inc.
InventorStephen Brand
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.
Claims27
A pharmaceutical composition comprising a first dose of a gastrin/cholecystokinin (CCK) receptor ligand, and a second dose of an epithelial growth factor (EGF) receptor ligand, wherein the first dose is between about 10-fold and about 100-fold by weight greater than the second dose and the composition is effective for inducing islet neogenesis in a subject in need of islet neogenesis.
6-37. (canceled)
A method of treating a diabetes patient in need of islet neogenesis, comprising:
- administering to the patient a composition comprising a first effective dose of a gastrin/CCK receptor ligand and an a second effective dose of an EGF receptor ligand, the composition being administered according to a dosing schedule of short duration;
- monitoring the blood glucose level in the patient following administering the composition;
- and reiterating administering the composition to the patient when an increase in blood glucose level indicates that the patient is in need of further islet neogenesis, such that the diabetes patient in need of islet neogenesis is treated.
(canceled)
42-52. (canceled)
A method of reducing exogenous insulin usage in an insulin-dependent diabetic patient, the method comprising:
- administering an effective dosage of a composition comprising a gastrin/CCK receptor ligand and an EGF receptor ligand, to induce islet neogenesis;
- and reducing the dose of exogenous insulin needed to prevent high blood glucose, whereby blood glucose is decreased.
(canceled)
(canceled)
(canceled)
A kit comprising a gastrin/CCK receptor ligand and an EGF receptor ligand wherein the gastrin/CCK receptor ligand is in a dose that is between about 10-fold and about 100-fold by weight greater than the dose of EGF receptor ligand.
65-68. (canceled)
Dependencies are inferred from the claim text.